Alzheimer's Disease Clinical Research
As of June 2012 there were more than 330 clinical trials under way to understand and treat Alzheimer's disease. 30 of these studies were human phase three trials, the last step before U.S. Food and Drug Administration approval and marketing.
There are different approaches. One approach is to reduce Amyloid beta, for example with bapineuzumab, an antibody in phase III studies for patients in mild to moderate stage; semagacestat, a γ-secretase inhibitor, MPC-7869; and acc-001 or CAD106, vaccines against amyloid beta. Other approaches are neuroprotective agents, like AL-108 (phase II completed); or metal-protein interaction attenuation, as is the case of PBT2 (phase II completed). Yet another approach is to use general cognitive enhances, as may be the case for memantine, a pharmaceutical approved in the United States and European Union to treat moderate-to-sever AD. Finally, there are basic investigations on the origin and mechanisms of Alzheimer's disease.
Read more about Alzheimer's Disease Clinical Research: Treatments in Clinical Development, Table of Advanced Disease-modifying Drug (DMD) Candidates
Famous quotes containing the words disease and/or research:
“It is the disease of not listening, the malady of not marking,
that I am troubled withal.”
—William Shakespeare (1564–1616)
“The great question that has never been answered and which I have not get been able to answer, despite my thirty years of research into the feminine soul, is “What does a women want?””
—Sigmund Freud (1856–1939)